| 195 | 1/2022 | Review | Polychronidis, Feng, Murtha-Lemekhova, Heger, et al | Factors Influencing Overall Survival for Patients with Fibrolamellar Hepatocellular Carcinoma: Analysis of the Surveillance, Epidemiology, and End Results Database |
| 194 | 7/2021 | Review | O'Neill, Church, Perez-Atayde, Vakili, et al. | Fibrolamellar carcinoma: An entity all its own |
| 193 | 6/2021 | Treatments | Lalazar, Requena, Torbenson, Simon, et al. | Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient Derived Xenografts and Direct from Patient Screening |
| 192 | 6/2021 | Case report | Solipuram, Baretti, Kim, Yarchoan, et al. | Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma |
| 191 | 3/2021 | Case report | Whitlock, Loo, Patel, Bista, et al. | Transarterial Radioembolization Treatment as a Bridge to Surgical Resection in Pediatric Hepatocellular Carcinoma |
| 190 | 3/2021 | Case report | Al Zahrani, Alfakeeh | Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports |
| 189 | 3/2021 | Mechanisms, pathways | Olivieri, Walker, Karamafrooz, et al. | Defective internal allosteric network imparts dysfunctional ATP/substrate-binding cooperativity in oncogenic chimera of protein kinase A |
| 188 | 3/2021 | Case report | Gottlieb, O'Grady, Gliksberg, Kent | Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma |
187
| 2/2021 | Case report | Matsumoto, Kikuchi, Hara, Tsunashima, et al. | Immunohistochemical detection of procalcitonin in fibrolamellar hepatocellular carcinoma |
| 186 | 12/2020 | Mechanisms, pathways | Lu, Aoto, Weng, Nielsen, et al | Structural analyses of the PKA RIIβ holoenzyme containing the oncogenic DnaJB1-PKAc fusion protein reveal protomer asymmetry and fusion-induced allosteric perturbations in fibrolamellar hepatocellular carcinoma |
| 185 | 9/2020 | Treatments | Lee, Jin, Ko, Kim, et al | Hyperammonemic Encephalopathy Mimicking Ornithine Transcarbamylase Deficiency in Fibrolamellar Hepatocellular Carcinoma: Successful Treatment with Continuous Venovenous Hemofiltration and Ammonia Scavengers |
| 184 | 8/2020 | Review | Samdanci, Akatli, Soylu
| Clinicopathological Features of Two Extremely Rare Hepatocellular Carcinoma Variants: a Brief Review of Fibrolamellar and Scirrhous Hepatocellular Carcinoma |
| 183 | 8/2020 | Treatments | Lamarca, Frizziero, Fulton, et al | Fibrolamellar carcinoma: Challenging the challenge |
| 182 | 7/2020 | Genomics | Abou-Alfa, El Dika, Bowman, Berger, et al | Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver |
| 181 | 6/2020 | Diagnostics | Du Toit, Aldera | Fibrolamellar Carcinoma With Predominantly Pseudoglandular Architecture: A Potential Diagnostic Pitfall |
| 180 | 5/2020 | Treatments | Gliksberg, O'Grady, Kent | Novel systemic therapies in hard to treat fibrolamellar hepatocellular carcinoma |
| 179 | 5/2020 | Diagnostics | Chen, de Gonzalez, Fazlollahi, et al | In situ hybridisation for albumin RNA in paediatric liver cancers compared with common immunohistochemical markers |
| 178 | 5/2020 | Clinical trial | El Dika, Mayer, Abou-Alfa, Capanu, et al | A Multicenter Randomized Three‐Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT ) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma |
| 177 | 5/2020 | Case report | Lemekhova, Hornuss, Polychronidis, et al | Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience |
| 176 | 4/2020 | Mechanisms, pathways | Dinh, Sethupathy | Hotspots of Aberrant Enhancer Activity in Fibrolamellar Carcinoma Reveal Candidate Oncogenic Pathways and Therapeutic Vulnerabilities |
| 175 | 3/2020 | Clinical trial | Abou-Alfa, Mayer, Gordan, Venook, et al | Phase II Multicenter, Open‐Label Study of Oral ENMD‐2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma |
| 174 | 2/2020 | Review | Assi, Mukherjee, Machiorlatti, Vesely, et al | Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database |
| 173 | 2/2020 | Modeling | De Oliviera, Huttenlocher | DnaJ-PKAc fusion induces liver inflammation in a zebrafish model of Fibrolamellar Carcinoma |
| 172 | 2/2020 | Diagnostics | Dong, Wang, Mao, Zhang, et al | Imaging Features of Fibrolamellar Hepatocellular Carcinoma with Contrast-Enhanced Ultrasound |
| 171 | 2/2020 | Case report | Ramai, Ofosu, Lai, Gao, et al | Fibrolamellar Hepatocellular Carcinoma: A Population-Based Observational Study |
| 170 | 1/2020 | Outcomes | Assi, Mukherjee, Macchiorlatti, et al | Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database |
| 169 | 1/2020 | Diagnostics | Anysz-Grodzicka, Podgorska, Cieszanowski | State-of-the-art MR Imaging of Uncommon Hepatocellular Tumours: Fibrolamellar Hepatocellular Carcinoma and Combined Hepatocellular cholangiocarcinoma |
| 168 | 1/2020 | Genomics | Dinh, Sritharan, Smith, et al | Hotspots of aberrant enhancer activity in fibrolamellar carcinoma reveal molecular mechanisms of oncogenesis and intrinsic drug resistance |
| 167 | 12/2019 | Genomics | Hirsch, Negulescu, Gupta, et al | BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA |
| 166 | 11/2019 | Case report | Balbeur, Brichard | DNAJB1‐PRKACA–positive metastatic fibrolamellar carcinoma with unknown primary in a pediatric patient |
| 165 | 11/2019 | Genomics | Vyas, Hechtman, Zhang, Benayed, et al | DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma |
| 164 | 10/2019 | Targeting | Jewell, Gibson, Guy, et al | Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1–Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma |
| 163 | 9/2019 | Modeling | De Oliviera, Huttenlocher, et al | DNAJB1-PRKACA fusion induces liver inflammation in zebrafish model of Fibrolamellar Hepatocellular Carcinoma |
| 162 | 9/2019 | Prognostics | Lafaro, Eng, Raoff, Melstrom, et al | A prognostic nomogram for patients with resected fibrolamellar hepatocellular carcinoma |
| 161 | 9/2019 | Mechanisms, pathways | Riehle, Kenerson, Riggle, et al | Neurotensin as a source of cyclic AMP and co-mitogen in fibrolamellar hepatocellular carcinoma |
| 160 | 7/2019 | Mechanisms, pathways | Karki, Putra, Kim, Laquaglia, et al | MDM4 expression in fibrolamellar hepatocellular carcinoma |
| 159 | 6/2019 | Case report | Bauer, Mogler, Braren, et al | Progression after Immunotherapy for Fibrolamellar Carcinoma |
| 158 | 6/2019 | Case report | Chalkrabarti, Tella, Kommalapati, et al | Clinicopathological features and outcomes of fibrolamellar
hepatocellular carcinoma |
| 157 | 5/2019 | Case report | Cho, Chen, Paludo, Conboy, et al | Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review |
| 156 | 5/2019 | Genomics | Turnham, Smith, Kenerson, Omar, et al | An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinoma |
| 155 | 4/2019
| Overview | Kastenhuber, Ramsey, Sullivan, Sage, et al | Road map for fibrolamellar carcinoma: progress and goals of a diversified approach |
| 154 | 3/2019 | Mechanisms, pathways | Kim, Gani, Layman. Besharati, et al | Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma |
| 153 | 1/2019 | Genomics | Dinh, Jewell, Kranke, Scott, Diehl | MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma |
| 152 | 1/2019 | Case report | Suarez, Perez, Garzon, Daza, et al | Fibrolamellar Hepatocellular Carcinoma and Noncirrhotic Hyperammonemic Encephalopathy |
| 151 | 11/2018 | Review | Chaudhari, Khobragade, Bhandare, Shrikhande | Management of fibrolamellar hepatocellular carcinoma |
| 150 | 9/2018 | Review | Lin, Yang | Fibrolamellar Carcinoma: A Concise Review |
| 149 | 8/2018 | Case report | Tanaka, Hijioka, Iwaya, Mizuno, et al | Fibrolamellar Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Multidisciplinary Therapy |
| 148 | 8/2018 | Case report | Bartlett, Leslie, Gupta, Geller | Acquired ornithine transcarbamylase deficiency in pediatric and adolescent patients with fibrolamellar hepatocellular carcinoma |
| 147 | 6/2018 | Radiology | Ganeshan,Szklaruk, Kaseb, Kattan, Elsayes | Fibrolamellar hepatocellular carcinoma: multiphasic CT features of the primary tumor on pre-therapy CT and pattern of distant metastases |
| 146 | 6/2018 | Case report | Shah, Kamboj, Cleary | Large Hepatic Mass in an Adolescent Male |
| 145 | 6/2018 | Pathology | Graham | Fibrolamellar Carcinoma What Is New and Why It Matters |
| 144 | 4/2018 | Case report | Ince, Isik, Ozdemir, et al | Living-Donor Liver Transplant for Fibrolamellar Hepatocellular Carcinoma With Hilar Lymph Node Metastasis: A Case Report |
| 143 | 3/2018 | Genomics | Farber, Lalazar, Simon, Hammond, et al | Non coding RNA analysis in fibrolamellar hepatocellular carcinoma |
| 142 | 2/2018 | Radiology | Palm, Sheng, Mayer, Weiss, et al | Imaging features of fibrolamellar hepatocellular carcinoma in gadoxetic acidenhanced MR |
| 141 | 2/2018 | Review | Lalazar, Simon | Fibrolamellar Carcinoma: Recent advances and unresolved questions on the molecular mechanisms |
| 140 | 2/2018 | Case report | Mafeld, French, Tiniakos, et al | Fibrolamellar Hepatocellular Carcinoma: Treatment with Yttrium-90 and Subsequent Surgical Resectio |
| 139 | 2/2018 | Case report | Bill, Montani, Blum, Dufour, et al | Favorable response to mammalian target of rapamycin inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver |
| 138 | 1/2018 | Genomics | Tomasini, Wang, Simon, et al | Conformational Landscape of the PRKACA-DNAJB1 Chimeric Kinase, the Driver for Fibrolamellar Hepatocellular Carcinoma |
| 137 | 12/2017 | Targeting | Stratakis | Cyclic AMP‐dependent protein kinase catalytic subunit A (PRKACA ): the expected, the unexpected, and what might be next |
| 136 | 12/2017 | Case report | Hammond, Lalazar, Saltsman, et al | Intracranial Metastasis in Fibrolamellar Hepatocellular Carcinoma |
| 135 | 12/2017 | Genomics | Graham, Lackner, Terracciano, et al | Fibrolamellar Carcinoma in the Carney Complex: PRKAR1A Loss Instead of the Classic DNAJB1-PRKACA Fusion |
| 134 | 11/2017 | Genomics | Kastenhuber, Lalazar, Houlihan, et al | DNAJB1–PRKACA fusion kinase interacts with β-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma |
| 133 | 10/2017 | Radiology | Semelka, Nimojan, Chandana, Ramalho, et al | MRI features of primary rare malignancies of the liver: A report from four university centres |
| 132 | 9/2017 | Genomics | Kastenhuber, Lalazar, Houlihan, Tschaharganeh, et al | DNAJB1-PRKACA fusion kinase interacts with β-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma |
| 131 | 9/2017 | Modeling | Engelholm, Riaz, Serra, et al | CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1–Prkaca Gene Fusion is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma |
| 130 | 9/2017 | Diagnostics | Graham, Yeh, Lam-Himlin, Roberts, et al | Molecular testing for the clinical diagnosis of fibrolamellar carcinoma |
| 129 | 8/2017 | Targeting | Cooney, Wei, Rangaswami | CD47 is not Over-Expressed in Fibrolamellar Hepatocellular Carcinoma |
| 128 | 6/2017 | SEER study | Nautsch, Ludwig, Xing, Johnson, Kim | Racial Disparities and Sociodemographic Differences in Incidence and Survival Among Pediatric Patients in the United States With Primary Liver Cancer A Surveillance, Epidemiology, and End Results (SEER) Population Study |
| 127 | 5/2017 | Case report | Ciurea, Matei, Stanescu, Lupescu, et al | Fibrolamellar hepatocellular carcinoma with ovarian metastasis - an unusual presentation |
| 126 | 5/2017 | Genomics | Sorenson, Khanin, Bamboat, Cavnar, et al | Genome and transcriptome profiling of fibrolamellar hepatocellular carcinoma demonstrates p53 and IGF2BP1 dysregulation |
| 125 | 5/2017 | Case report | Andrade, de Lima, de Faria, Vargas | TP53 germline and somatic mutations in a patient with fibrolamellar hepatocellular carcinoma |
| 124 | 3/2017 | Pathology | Kim, Rhee. Yoo. Alves, et al | Tumour epithelial and stromal characteristics of hepatocellular carcinomas with abundant fibrous stroma: fibrolamellar versus scirrhous hepatocellular carcinoma |
| 123 | 3/2017 | Case report | Vishnu, Kulkarni, Vidhyalakshmi, et al | Fibrolamellar variant of hepatocellular carcinoma presenting during pregnancy: management dilemmas |
| 122 | 3/2017 | Genomics | Dinh, Vitucci, Wauthier, Graham, et al | Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma |
| 121 | 3/2017 | Review | Wahab, Hanafy, Nakeeb, Ali | Clinicopathological features and surgical outcome of patients with fibrolamellar hepatocellular carcinoma (experience with 22 patients over a 15-year period) |
| 120 | 3/2017 | Case report | Surjan, dos Santos, Basseres, Makdissi, Machado | A Proposed Physiopathological Pathway to Hyperammonemic Encephalopathy in a Non-Cirrhotic Patient with Fibrolamellar Hepatocellular Carcinoma without Ornithine Transcarbamylase (OTC) Mutation |
| 119 | 3/2017 | Case report | Graham, Craig, Jin, Olivera, et al | Environmental exposures as a risk factor for fibrolamellar carcinoma |
| 118 | 1/2017 | Review | Graham, Torbenson | Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings |
| 117 | 12/2016 | Case report | Hernandez, Ruiz, Torre | Duodenal Recurrence of Fibrolamellar Carcinoma 12 Years After Partial Hepatectomy and Adjuvant Chemotherapy |
| 116 | 11/2016 | Treatments | Atienza, Berger, Mei, Shah, et al | Liver transplantation for fibrolamellar hepatocellular carcinoma: A national perspective |
| 115 | 11/2016 | Case report | Alsina, Franco, Nakshabandi, et al | Successful Liver Transplantation for Hyperammonemic Fibrolamellar Hepatocellular Carcinoma |
| 114 | 8/2016 | Case report | Diez, Higueras, Zafra, et al | Fibrolamellar hepatocellular carcinoma: a rare entity diagnosed by abdominal ultrasound |
| 113 | 7/2016 | Review | Yamashita, Vauthry, Kaseb, Aloia, et al | Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma |
| 112 | 5/2016 | Review | Kassahun | Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments |
| 111 | 5/2016 | Case report | Bernieh, Adams, Liu, Flowers, et al | Fibrolamellar hepatocellular carcinoma in ascitic fluid: A case report with cytohistological correlation |
| 110 | 4/2016 | Case report | Griffith, Griffith, Krysiak, Magrini, et al | A Genomic Case Study of Mixed Fibrolamellar Hepatocellular Carcinoma |
| 109 | 3/2016 | Mechanisms, pathways | Riggle, Riehle, Kenerson, Turnham, et al | Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma |
| 108 | 3/2016 | Review | Riggle, Turnham, Scott, Yeung, et al | Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma |
| 107 | 3/2016 | Case report | Chapuy, Sahai, Sharma, Zhu, Kozyreva | Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm |
| 106 | 2/2016 | Diagnostics | Sergi | Hepatocellular Carcinoma, Fibrolamellar Variant: Diagnostic Pathologic Criteria and Molecular Pathology Update. A Primer |
| 105 | 12/2015 | Case report | Limaiem, Bouraoui, Sboui, Lahmar, et al | Fibrolamellar carcinoma versus scirrhous hepatocellular carcinoma : diagnostic usefulness of CD68 |
| 104 | 11/2015 | SEER study | Lau, Mahendraraj, Chamberlain | Hepatocellular Carcinoma in the Pediatric Population: A Population Based Clinical Outcomes Study Involving 257 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973–2011) |
| 103 | 11/2015 | SEER study | Jernigan, Wima, Hanseman, Hoehn, et al | Natural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry |
| 102 | 10/2015 | Modeling | Patman | A model of fibrolamellar carcinoma |
| 101 | 10/2015 | Genomics | Simon, Freije, Farber, Lalazar, et al | Transcriptomic characterization of fibrolamellar hepatocellular carcinoma |
| 100 | 10/2015 | Genomics | Reid, Sethupathy | The DNAJB1‐PRKACA chimera: Candidate biomarker and therapeutic target for fibrolamellar carcinomas |
| 99 | 10/2015 | Modeling | Oikawa, Wauthier, Dinh, Selitsky, et al | Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells |
| 98 | 9/2015 | Case report | Villa, Pannala, Faigel, Haakinson, et al | Metastatic Fibrolamellar Hepatocellular Carcinoma to the Pancreas |
| 97 | 8/2015 | Genomics | Graham, Garcia, Griepp,Barr Fritcher, Kipp, Torbenson | FGFR1 and FGFR2 in fibrolamellar carcinoma |
| 96 | 8/2015 | Genomics | Malouf, Tahara, Paradis, Fabre, et al | Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive feature |
| 95 | 5/2015 | Case report | Chagas, Kikuchi, Herman, Alencar, et al | Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 cases |
| 94 | 4/2015 | Case report | Arora | Fibrolamellar Hepatocellular Carcinoma Presenting as Obstructive Jaundice: Uncommon Presentation of a Rare Entity |
| 93 | 4/2015 | Editorial | Andersen | Fibrolamellar Hepatocellular Carcinoma: A Rare but Distinct Type of Liver Cancer |
| 92 | 2/2015 | Genomics | Graham, Jin, Knutson, Kloft-Nelson, et al | DNAJB1-PRKACA is specific for fibrolamellar carcinoma |
| 91 | 1/2015 | Genomics | Cornella, Alsinet. Sayols, Zhang, et al | Unique genomic profile of fibrolamellar hepatocellular carcinoma |
| 90 | 1/2015 | Genomics | Darcy, Chiaroni-Clarke, Murphy, et al | The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients |
| 89 | 1/2015 | Prognostics | Darcy, Malek, Kobos, et al | Prognostic factors in fibrolamellar hepatocellular carcinoma in young people |
| 88 | 12/2014 | Review | Lim. Farber, LaQuaglia | Advances in fibrolamellar hepatocellular carcinoma: a review |
| 87 | 12/2014 | Treatments | Herman, Chagras, Perini, Coelho, et al | Surgical treatment of fibrolamellar hepatocellular carcinoma: an underestimated malignant tumor? |
| 86 | 8/2014 | Genomics | Xu, Hazard, Zmoos, Jahchan, et al | Genomic analysis of fibrolamellar hepatocellular carcinoma |
| 85 | 7/2014 | Case report | Sulaiman, Geberhiwot | Fibrolamellar Hepatocellular Carcinoma Mimicking Ornithine Transcarbamylase Deficiency |
| 84 | 7/2014 | Case report | Fonseca, Varella, Coelho, Abe, et al | Downstaging and resection after neoadjuvant therapy for fibrolamellar hepatocellular carcinoma |
| 83 | 6/2014 | Signalling | Riehle, Yeh, Yu, Kenerson, et al | mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma |
| 82 | 6/2014 | SEER study | Eggert, McGlynn, Duffy, Manns, et al | Fibrolamellar hepatocellular carcinoma in the USA, 2000–2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results databas |
| 81 | 6/2014 | Case report | Chiarelli, De Simone, Guttadauro, Cioffi | Fibrolamellar carcinoma in a 62 year-old patient with human immunodeficiency virus infection |
| 80 | 6/2014 | Diagnostics | Do, McErlean, Ang, et al | CT and MRI of primary and metastatic fibrolamellar carcinoma: a case series of 37 patients |
| 79 | 5/2014 | Review | Groeschl, Miura, Wong, Bloomston, et al | Multi‐institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma |
| 78 | 3/2014 | Case report | Okur, Eser, Yilmaz, Dalgic, et al | Successful Multimodal Treatment for Aggressive Metastatic and Recurrent Fibrolamellar Hepatocellular Carcinoma in a Child |
| 77 | 2/2014 | Genomics | Honeyman, Simon, Robine, Clarke, et al | Detection of a Recurrent DNAJB1-PRKACA Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma |
| 76 | 2/2014 | Diagnostics | Ganeshan, Szklaruk, Kundra, Kaseb, et al | Imaging Features of Fibrolamellar Hepatocellular Carcinoma |
| 75 | 1/2014 | Genomics | Malouf, Job, Paradis, Fabre, et al | Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature |
| 74 | 1/2014 | SEER study | Basile | Long-term Survival of Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A US Population-based Study |
| 73 | 1/2014 | Review | Allan, Wang, Davis, et al | A review of 218 pediatric cases of hepatocellular carcinoma |
| 72 | 12/2013 | Review | Mayo, Mavros, Nathan, et al | Treatment and Prognosis of Patients with Fibrolamellar Hepatocellular Carcinoma: A National Perspective |
| 71 | 11/2013 | Case report | Peacock, Call, Olivier | Radiotherapy for metastatic fibrolamellar hepatocellular carcinoma |
| 70 | 9/2013 | Review | Kaseb, Sharma, Sahin, Nooka, et al | Treatment outcome and prognostic indicators in 94 cases of fibrolamellar hepatocellular carcinoma |
| 69 | 8/2013 | Case report | Minutolo, Licciardello, Arena, Minutolo, et al | Surgical Resection of Ruptured Fibrolamellar Hepatocellular Carcinoma |
| 68 | 7/2013 | Case report | De Gaetano, Nure, Grossi, Frongillo, et al | Fibrolamellar hepatocellular carcinoma with biliary tumor thrombus: an unreported association |
| 67 | 7/2013 | Case report | Matsuda, Amemiya, Kawaida, Okamoto, et al | Typical fibrolamellar hepatocellular carcinoma in a Japanese boy: report of a case |
| 66 | 7/2013 | Review | Kaseb, Sharma, Sahin, Nooka, et al | Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar Hepatocellular Carcinoma |
| 65 | 5/2013 | Epidemiology | Eggert, McGlynn, Duffy, Manns, et al | Epidemiology of fibrolamellar hepatocellular carcinoma in the U.S., 2000–2010 |
| 64 | 5/2013 | Review | Weeda, Murawski, McCabe, et al | Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma – Results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience |
| 63 | 5/2013 | Case report | Fakih | A Case of Fibrolamellar Cancer With a Palliative Response and Minor Radiographic Regression With Erlotinib and Bevacizumab Combination Therapy |
| 62 | 3/2013 | Review | Ang, Kelley, Choti, Cosgrove, et al | Clinicopathologic Characteristics and Survival Outcomes of Patients With Fibrolamellar Carcinoma: Data From the Fibrolamellar Carcinoma Consortiu |
| 61 | 1/2013 | Case report | Singh, Ramakrishna | Combined Hepatocellular Carcinoma and Fibrolamellar Carcinoma Presenting as Two Adjacent Separate Lesions in a Young Boy: First Case Report from Asia |
| 60 | 10/2012 | Case report | Berger, Dimant, Hermida, Paulin, et al | Hyperammonemic encephalopathy and fibrolamellar hepatocellular carcinoma |
| 59 | 9/2012 | Review | Mavros, Mayo, Hyder, et al | A Systematic Review: Treatment and Prognosis of Patients with Fibrolamellar Hepatocellular Carcinoma |
| 58 | 8/2012 | Genomics | Patonai, Erdelyi-Belle, Korompay, et al | Molecular Characteristics of Fibrolamellar Hepatocellular Carcinoma |
| 57 | 3/2012 | Case report | Gras, Truant, Boige, Ladrat, et al | Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma |
| 56 | 3/2012 | Case report | Knudson, Goldberg, Ayres | Fibrolamellar hepatocellular carcinoma with cardiac spread causing severe inferior vena cava obstruction in a 9-year-old child |
| 55 | 3/2012 | Review | Malouf, Brugieres, Le Deley, Faivre, et al | Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection |
| 54 | 2/2012 | Case report | Benito, Segura, Martinez. et al | Fibrolamellar hepatocellular carcinoma metastatic to the ovary |
| 53 | 1/2012 | Case report | Ko, Verhoeven, Lee, Corbin, Vogl and Pedersen | A Translational Study "Case Report" on the Small Molecule "Energy Blocker" 3Bromopyruvate (3BP) as a Potent Anticancer Agent: From Bench Side to Bedside |
| 52 | 1/2012 | Mechanisms, pathways | Wilczek, Szparecki, Lukasik, Koperski | Loss of the Orphan Nuclear Receptor SHP Is More Pronounced in Fibrolamellar Carcinoma than in Typical Hepatocellular Carcinom |
| 51 | 1/2012 | Review | Torbenson | FibrolamellarCarcinoma:2012Update |
| 50 | 5/2011 | Case report | Muramori, Taguchi, Taguchi, Kohashi, et al | High Aromatase Activity and Overexpression of Epidermal Growth Factor Receptor in Fibrolamellar Hepatocellular Carcinoma in a Child |
| 49 | 4/2011 | Markers | Patonai, Erdelyi-Belle, Korompay, Somoracz, et al | Claudins and tricellulin in fibrolamellar hepatocellular carcinoma |
| 48 | 4/2011 | Case report | Liu, Chan, Tong, Wang, et al | PET–CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellular carcinoma: a case report and a summary of recent literature |
| 47 | 2/2011 | Review | Ward, Waxman | Fibrolamellar Carcinoma: A Review with Focus on Genetics and Comparison to Other Malignant Primary Liver Tumors |
| 46 | 12/2010 | Review | Dhingra, Li, Tan, Zenali, et al | Cell cycle biology of fibrolamellar hepatocellular carcinoma |
| 45 | 11/2010 | Genomics | Ross, Daniel, Vivekanandan, Kannangai, et al | Fibrolamellar Carcinomas are Positive for CD68 |
| 44 | 11/2010 | Markers | Lidballe, Nguyen, Poulsen, et al | Haptocorrin as marker of disease progression in fibrolamellar hepatocellular carcinoma |
| 43 | 11/2010 | Genomics | Trankenschuh, Puls, Christgen, Albat, et al | Frequent and Distinct Aberrations of DNA Methylation Patterns in Fibrolamellar Carcinoma of the Liver |
| 42 | 5/2010 | Review | Ward, Huang, Tickoo, Thung | Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation |
| 41 | 5/2010 | Comparative | Abdul-Al, Wang, Mahklouf | Fibrolamellar Hepatocellular Carcinoma: An Immunohistochemical Comparison With Conventional Hepatocellular Carcinoma |
| 40 | 4/2010 | Comparative | Zenali, Tan, Li, Dhingra, Brown | Stemness characteristics of fibrolamellar hepatocellular carcinoma: immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma |
| 39 | 3/2010 | Genomics | Vivekanandan, Daniel, Yeh, Torbenson | Mitochondrial Mutations in Hepatocellular Carcinomas and Fibrolamellar Carcinomas |
| 38 | 3/2010 | Mechanisms, pathways | Li, Tan, Zenali, Brown | Constitutive activation of nuclear factor-kappa B (NF-κB) signaling pathway in fibrolamellar hepatocellular carcinom |
| 37 | 2/2010 | Case report | Bhanjee, Locketz, Krige | Fibrolamellar hepatocellular carcinoma at a tertiary centre in South Africa: a case series |
| 36 | 12/2009 | Case report | Sethi, Tageja, Dave, et al | Hyperammonemic Encephalopathy: A Rare Presentation of Fibrolamellar Hepatocellular Carcinoma |
| 35 | 12/2009 | Case report | Terzis, Haritanti, Economou | Fibrolamellar Hepatocellular Carcinoma: a Case Report with Distinct Radiological Feature |
| 34 | 7/2009 | Review | Liu, Chan, Wang, Qiao | Fibrolamellar hepatocellular carcinoma |
| 33 | 7/2009 | Case report | Butte, Waugh, Meneses, Pruzzo, et al | Fibrolamellar liver carcinoma: report of two cases and review of the literature |
| 31 | 11/2008 | Genomics | Kakar, Chen, Ho, Burgart, et al | Chromosomal changes in fibrolamellar hepatocellular carcinoma detected by array comparative genomic hybridization |
| 30 | 11/2008 | Genomics | Vivekanandan, Shien, Torenson | Anterior Gradient-2 is Over Expressed by Fibrolamellar Carcinomas |
| 29 | 3/2008 | Case report | Smith, Blatt, Jedicka, Strain, Fenton | Fibrolamellar Hepatocellular Carcinoma |
| 28 | 2/2008 | Genomics | Vivekanandan, Torenson | Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas |
| 27 | 5/2007 | Case report | Meriggi, Forni | Surgical therapy of hepatic fibrolamellar carcinoma |
| 26 | 4/2007 | Review | Torbenson | Review of the Clinicopathologic Features of Fibrolamellar Carcinoma |
| 25 | 3/2007 | Genomics | Kannangai, Vivekanandan, Martinez-Murillo, Choti, et al | Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways |
| 24 | 10/2005 | Case report | Imkie, Myers, Li, Fan, et al | Fibrolamellar hepatocellular carcinoma arising in a background of focal nodular hyperplasia: a report of 2 cases |
| 23 | 10/2005 | Case report | Zermani, Charfi, Kourda, Farah, et al | A particular hepatocellular carcinoma combining the ordinary and the fibrolamellar variant |
| 22 | 9/2005 | Pathology | Klein, Molmenti, Colombani, Grover, et al | Primary Liver Carcinoma Arising in People Younger Than 30 Years |
| 20 | 5/2005 | Pathology | Kakar, Burgart, Batts, Gacia, et al | Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis |
| 19 | 12/2004 | Mechanisms, pathways | Sahin, Kannangai, Adegbola, Wang, et al | mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms |
| 18 | 8/2004 | Case report | Kanai, Takabayashi, Kawano, et al | A Case of Postoperative Recurrence of Fibrolamellar Hepatocellular Carcinoma with Increased Vitamin B12 Binding Capacity in a Young Japanese Female |
| 17 | 3/2004 | Diagnostics | Vasdev, Nayak | CD99 expression in hepatocellular carcinoma: an immunohistochemical study in the fibrolamellar and common variant of the tumour |
| 16 | 3/2004 | SEER study | El-Serag, Davila | Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population‐based study |
| 15 | 1/2004 | Case report | Terracciano, Tornilla, Avoledo, et al | Fibrolamellar hepatocellular carcinoma occurring 5 years after hepatocellular adenoma in a 14-year-old girl: a case report with comparative genomic hybridization analysis |
| 14 | 12/2003 | Case report | Kitabayashi, Yokoi, Ueno, Saito, et al | Fibrolamellar hepatocellular carcinoma: report of a case |
| 13 | 4/2003 | Review | Katzenstein, Krailo, Malogolowkin, Ortega, et al | Fibrolamellar hepatocellular carcinoma in children and adolescents |
| 11 | 2/2003 | Clinical trial | Patt, Hassan, Lozano, Brown, et al | Phase II Trial of Systemic Continuous Fluorouracil and Subcutaneous Recombinant Interferon Alfa-2b for Treatment of Hepatocellular Carcinoma |
| 10 | 11/2002 | Guidelines | Ryder | Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults |
| 9 | 8/2002 | Review | Arista-Nasr, Gutierrez-Villalobos, Nuncio, Maldonato, et al | Fibrolamellar hepatocellular carcinoma in mexican patients |
| 8 | 1/2002 | Diagnostics | Wang, Cui, Yu | Imaging findings of fibrolamellar hepatocellular carcinoma |
| 7 | 6/2001 | Genomics | Sirivatanauksorn, Sirivatanauksorn, Lemoine, Williamson, Davidson | Genomic homogeneity in fibrolamellar carcinomas |
| 6 | 5/2001 | Case report | Braune, Frangmann, Scheumann, Klempnauer | Multiorgan resection in combination with intraoperative, hyperthermic chemotherapy in recurrent fibrolamellar hepatocellular carcinoma. An individual therapeutic concept for a 21-year-old patient |
| 5 | 5/2001 | Genomics | Wilkins, Bredt, Flemming, Kubicka, et al | Cytogenetic Aberrations in Primary and Recurrent Fibrolamellar Hepatocellular Carcinoma Detected by Comparative Genomic Hybridization |
| 4 | 12/2000 | Review | El-Gazzaz, Wong, El-Hadary, Gunson, et al | Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma |
| 3 | 9/2000 | Diagnostics | Ichikawa, Federle, Grazioli, Marsh | Fibrolamellar Hepatocellular Carcinoma: Pre- and Posttherapy Evaluation with CT and MR Imaging |
| 2 | 7/1988 | Case report | Berman, Burnhamet and Sheahan | Fibrolamellar carcinoma of the liver: An immunohistochemical study of nineteen cases and a review of the literature |
| 1 | 8/1982 | Marker | Paradinas, Melia, Wilkinson, Portmann et al. | High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma |
